EPOCH: Phase III Trial Comparing Transarterial Radioembolization With Yttrium-90 + Second-line CT vs CT Only in Patients With Unresectable Colorectal Liver Metastases

Phase II trial evaluating pemigatinib for previously treated mCRC with FGF/FGFR alterations, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

MOUNTAINEER concordance analysis between breast and gastric algorithms for HER2 testing in mCRC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

SUNLIGHT trial of the addition of bevacizumab to third-line TAS-102 in refractory mCRC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

In slides from Clinical Care Options (CCO), experts provide perspectives on updates in biomarker testing and targeted therapy across GI cancers

John L. Marshall, MD
Program Director Christopher H. Lieu, MD Manish A. Shah, MD Released: January 19, 2023